Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.38 +0.06 (+0.24%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval
Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients 
Via Benzinga
RFK Jr. Champions 'Medical Freedom' While Curtailing Access, Say Public Health Experts
U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health... 
Via Benzinga
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
Via The Motley Fool
Topics Intellectual Property Retirement
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
A volatile stock market represents an ideal opportunity for long-term investors to pounce. 
Via The Motley Fool
Topics Stocks
Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma
Via Benzinga
P/E Ratio Insights for Pfizer
Via Benzinga
S&P 500 Earnings Stun The Street In Q1 With Broad-Based Beats, Double-Digit Growth
Nearly 80% of S&P 500 firms beat Q1 earnings forecasts. Profit growth hit 13.3%, led by tech and health care, says FactSet. 
Via Benzinga
Topics Stocks
These 2 Dow Stocks Are Set to Soar in 2025 and Beyond
Apple and Cisco could generate surprising gains over the next few years. 
Via The Motley Fool
Topics Artificial Intelligence Economy Government
3 Safe Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 11.35% -- That Make for No-Brainer Buys in June
Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond. 
Via The Motley Fool
Why BioNTech Stock Soared Today
Bristol Myers Squibb just agreed to shower BioNTech with cash. 
Via The Motley Fool
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Pfizer (NYSE:PFE)
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer (NYSE:PFE) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Terrible News for Pfizer Stock Investors
Via The Motley Fool
Beat the S&P 500 With This Cash-Gushing Dividend Stock
The business may be somewhat boring, but it consistently delivers year after year, resulting in tremendous long-term returns. 
Via The Motley Fool
Topics Artificial Intelligence Bonds Intellectual Property
Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%
Pfizer's BRAFTOVI combo cut death risk by 51% and more than doubled survival in BRAF-mutant colorectal cancer in a Phase 3 trial. 
Via Benzinga
2 Large-Cap Stocks to Target This Week and 1 to Keep Off Your Radar
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an... 
Via StockStory
Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For 'Healthy' Pregnant Women, Children
RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed. 
Via Benzinga
Is Pfizer Stock a Buy After This $1.25 Billion Investment?
Via The Motley Fool
Down 63%, Should You Buy the Dip on Pfizer?
Pfizer has taken its lumps lately. It's time to wonder whether the stock can make a comeback. 
Via The Motley Fool
Topics Economy Government World Trade
1 Ultra-High-Yield Dividend Stock Down 57% to Buy Hand Over Fist
Via The Motley Fool
Topics Government Intellectual Property World Trade
U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result
There's little doubt these pharmaceutical companies' costs will soon be rising at least a little. 
Via The Motley Fool
Topics Government Supply Chain World Trade
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
Pfizer's high dividend yield warrants scrutiny regarding its sustainability, given changing revenues and pipeline investments. 
Via MarketBeat
Pfizer Stock Analysis: Buy, Sell, or Hold?
Via The Motley Fool
3 Stocks Under $10 Skating on Thin Ice
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be... 
Via StockStory
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
FDA Limits Annual COVID-19 Boosters To High-Risk Americans, Demands New Trials For Healthy Adults In Policy Shift Under RFK Jr.
The U.S. Food and Drug Administration has announced significant changes to COVID-19 vaccine requirements, limiting annual booster approvals to older and high-risk Americans while implementing stricter... 
Via Benzinga
2 High-Yield Dividend Stocks to Buy Right Now
Via The Motley Fool
Topics Earnings Intellectual Property
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Topics Economy Law Enforcement
Stay informed about the most active stocks in the S&P500 index on Tuesday's session.
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention. 
Via Chartmill
Pfizer Stock Is Trading Higher Tuesday: What's Going On?
Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on. 
Via Benzinga
FDA Sets New Guidelines For Approving COVID-19 Booster Shots In Healthy Individuals: Moderna, Novavax Stocks Rise
The agency plans to demand stronger evidence of efficacy for the shots before approval is granted for healthy persons, between the ages of six months and 64 years, with no risk factors for severe... 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.